Dogs with atopic dermatitis treated with APOQUEL® experienced persistent improvement in skin lesions4
skin lesions assessed by dermatologists
In a randomised double-blinded study, 299 client-owned dogs with moderate to severe pruritus, and a history of chronic atopic dermatitis were treated with either APOQUEL® (n=152) or placebo (n=147). Severity of dermatitis (CADESI-02)* was assessed by dermatologists before and after treatment throughout the 4 month study.
* CADESI-02: The Canine Atopic Dermatitis Extent and Severity Index is a scoring system used to assess canine atopic dermatitis severity. It is based on 3 parameters (erythema, lichenification and excoriation) and on the extent of the lesions. 40 body sites are evaluated.
** Open Label: Dogs with worsening pruritus and/or AD that had been on study to day 14 could be withdrawn and then enrolled in an open label study, in which every dog received APOQUEL® at a dose of 0.4–0.6 mg/kg once daily.4
apoquel® was evaluated in a long-term field study 10